Senores Pharmaceuticals Ltd. Corporate Filings & Announcements

Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 ,inter alia, to consider and approve Unaudited and Consolidated Financial Results of the Company for quarter and nine months ended December 31, 2024 and to transact any other business matters.

pdf

Senores Pharmaceuticals Ltd.

09 Jan 2025

711.75

-0.13%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Senores Pharmaceuticals receives ANDA approval for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg.

pdf

Senores Pharmaceuticals Ltd.

01 Jan 2025

711.75

-0.13%

Company Update

Senores Pharmaceuticals Ltd - 544319 - Intimation Under Regulation 30(5) Of The SEBI (LODR) Regulations, 2015.

BSE India

Intimation under Regulation 30(5) of the SEBI (LODR) Regulations, 2015.

pdf

Senores Pharmaceuticals Ltd.

31 Dec 2024

711.75

-0.13%

SAST

Senores Pharmaceuticals Ltd - 544319 - Closure of Trading Window

BSE India

Intimation regarding closure of trading window, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, from January 01, 2025 till 48 hours after announcement/declaration of financial results for quarter and nine months ending on December 31, 2024

pdf

Senores Pharmaceuticals Ltd.

30 Dec 2024

711.75

-0.13%

Corp. Note

Senores Pharmaceuticals Ltd - 544319 - Listing of Equity Shares of Senores Pharmaceuticals Ltd

BSE India

Trading Members of the Exchange are hereby informed that effective from December 30, 2024, the equity shares of Senores Pharmaceuticals Ltd (Scrip Code: 544319) are listed and admitted to dealings on the Exchange in the list of ''B'' Group Securities. For further details please refer to the notice no. 20241227-51 dated December 27, 2024.

RESEARCH REPORTS

SEE REPORTS >

pdf